Sygnature Discovery announces ambitious expansion plan with addition of Alderley Park facility
15 August 2018 - Sygnature Discovery, a leading independent provider of integrated drug discovery and pre-clinical services and expertise, has today announced the next stage in its ambitious expansion plans with the addition of a new facility located at Alderley Park in Cheshire.
This expansion will result in the doubling of Sygnature’s drug metabolism and pharmacokinetics (DMPK) department as the company embarks on a sustained recruitment programme. The expanded DMPK department, which focuses on the timely delivery and interpretation of discovery DMPK data to pharmaceutical and biotechnology companies through innovation, quality and commitment, will be co-located across Sygnature’s Nottingham and Alderley Park sites.
Commenting on the announcement, Chief Operating Officer, Dr Jonathan Williams said: “The demand for our DMPK services and expertise is growing rapidly year on year, so we are expanding the team and bringing in more expertise to meet this growing client need. Following our move into the Discovery Building at BioCity Nottingham in 2017, we have the space to continue to grow the company, but we appreciate that skilled scientists can also be found in other locations. The North West has a wealth of expertise in the field of DMPK and as Alderley Park is home to the UK's largest life science campus we wanted to align our growth with theirs.
“To effectively manage our DMPK department across two sites and to retain Sygnature Discovery’s unique culture and values, which have been instrumental to our success, some of the Nottingham-based DMPK team will be relocating to Alderley Park.
“As a business we have seen significant growth outside of the UK in recent years and we are now focusing heavily on the further expansion of our global client base. Clients come to Sygnature because we are able to offer not only a high quality fully-integrated drug discovery service, but we also have the flexibility to provide DMPK, medicinal chemistry and in vitro biology as stand-alone services.”
Sygnature Discovery launched its DMPK department in January 2015 with the appointment of Dr Tim Schulz-Utermoehl as Director, who joined from Shire Pharmaceuticals. Since then, Tim has greatly expanded the department, recruiting specialist scientists, and added additional capabilities, most recently discovery toxicology.
Sygnature’s DMPK scientists are highly-experienced with half of the department having over ten years’ experience in their field of expertise. This, combined with the broader integrated drug discovery service-offering, gives Sygnature Discovery an enviable reputation and unique position in the market.
This new exciting phase of growth for Sygnature will see the DMPK department doubling in size over the next 18 months as the recruitment programme is implemented.